The Role of AI in Amazon’s Success
Amazon (AMZN 1.73%) is widely recognized as an e-commerce giant that delivers packages swiftly, often on the same day as the order. Behind their operational efficiency and seamless fulfillment processes lies the integration of AI technology.
While Amazon has been leveraging AI for some time, the company has recently increased its investments in this field. AI optimizes e-commerce operations, leading to cost reductions for Amazon. Moreover, it enhances customer service, encouraging repeat business and generating more revenue for the company.
Amazon’s cloud computing service, Amazon Web Services (AWS), has also seen a significant increase in AI investments. A standout example is Amazon Bedrock, which provides clients with pre-built foundation models to scale their generative AI applications effortlessly.
As AI continues to bolster profitability in both Amazon’s e-commerce and cloud computing businesses, the correlation between earnings growth and share-price gains increases shareholders’ confidence in the company’s future performance.
Unlocking the Potential of Gene Editing with CRISPR Therapeutics
CRISPR Therapeutics (CRSP -1.37%) has undertaken a fruitful partnership with Amazon, focusing on gene editing—a process that rectifies genetic abnormalities causing diseases. CRISPR Therapeutics employs a technique called CRISPR/Cas9 gene editing, and its collaboration with Amazon has resulted in the development of Casgevy, a breakthrough treatment for blood disorders.
Casgevy holds the distinction of being the first-ever regulatory-approved therapy based on CRISPR gene-editing technology. The promise of gene-editing products lies in their potential to deliver functional cures, making them highly sought-after by physicians and patients, despite the somewhat cumbersome treatment process. For instance, Casgevy treatment spans several months and requires the collection of blood stem cells, among other stages.
Vertex, a trusted partner of CRISPR Therapeutics, envisions the technology’s immense potential and has licensed it for use in its type 1 diabetes (T1D) program. With Casgevy serving as a catalyst, gene-editing therapies could usher in a new era of growth for Vertex.